IDH1 and central nervous system cancer: Peptides including the mutated region were presented with MHC class II molecules and elicited a mutated specific CD4+ (TH1) immune response in mice models with IDH1 mutated gliomas, making it a possible neo-antigen for IDH1 mutated AMLs [39].